Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AVID 100 (Primary)
Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Forbius

22 Mar 2021 Status changed from active, no longer recruiting to discontinued.
21 Oct 2020 Planned End Date changed from 1 Dec 2020 to 30 Jan 2021.
21 Oct 2020 Planned primary completion date changed from 1 Sep 2020 to 28 Nov 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com